ArticleJournal of cardiothoracic surgery2025
Clinical significance of lncRNA PAX8-AS1 and miR-96-5p in non-small cell lung cancer.
Article in Journal of cardiothoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The lncRNA ZNF295-AS1 alleviates lung squamous cell carcinoma progression by reducing miR-96-5p and inhibiting cancer cell invasiveness.RNA biology · 2026Article
- Reduced Expression of LINC01515 Suppresses Proliferation and Invasion of Lung Adenocarcinoma Cells via Modulation of the miR-33a-5p/HMGA2 Signaling Axis.Current medicinal chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThis study aims to examine the potential value of lncRNA PAX8-AS1 and miR-96-5p as diagnostic markers in non-small cell lung cancer (NSCLC). The goal is to provide a reference for improving adverse outcomes in NSCLC and developing effective early interventions in the clinic.
methodsA total of 112 NSCLC patients and 70 healthy volunteers were recruited as the study subjects. The expression levels of PAX8-AS1 and miR-96-5p were measured using fluorescence quantitative PCR. The expression levels of PAX8-AS1 and miR-96-5p were detected by fluorescence quantitative PCR. A dual luciferase reporter assay was used to detect the binding of PAX8-AS1 and miR-96-5p. ROC, Kaplan-Meier, and Cox regression analysis was used to assess the diagnostic and prognostic value of PAX8-AS1 and miR-96-5p in NSCLC.
resultsIn NSCLC, PAX8-AS1 was found to be downregulated, whereas miR-96-5p was upregulated. These two molecules exhibited a negative correlation and a target-binding relationship. Receiver operating characteristic (ROC) curve analysis demonstrated that PAX8-AS1 and miR-96-5p had practical diagnostic values for distinguishing NSCLC patients. Mortality increased in NSCLC patients with low PAX8-AS1 levels and decreased in those with low miR-96-5p levels. Cox regression analysis showed that PAX8-AS1 and miR-96-5p could serve as independent predictors of prognostic survival in NSCLC patients.
conclusionPAX8-AS1 and miR-96-5p can serve as potential diagnostic biomarkers for NSCLC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.